- Home
- Products
- Customized FluoroAb™
- ERBB2
- Margetuximab-iFluor 350
Margetuximab-iFluor 350 (CAT#: ADC-FL-1351)
- TARGET
- ANTIBODY
- DYE
- Name
- ERBB2
- Alternative Names
- ERBB2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); NGL, v erb b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog); receptor tyrosine-prEGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown he
- Overview
- This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
- Overview
- Chimeric Anti-ERBB2 IgG1-kappa antibody,Margetuximab
- Generic name
- Margetuximab
- Species Reactivity
- Human
- Name
- iFluor 350
- Color
- Blue
- Excitation⁄Emission (nm)
- 346/442
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-FL-1351. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-514 | Anti-ERBB2 (Trastuzumab)-VC-DUBA ADC | VC (valine-citrulline) | seco-DUBA (DUocarmycin hydroxyBenzamide Azaindole) |
| ADC-W-2596 | Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2597 | Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-1115 | Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-1116 | Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-TNFRSF9 MAb (Clone 10)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS12296)
- Anti-VEGFA MAb (Clone 11)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS15392)
- Anti-ACVR2B MAb (Clone 5)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS5686)
- Anti-CD22 MAb (Clone 36)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS11655)
- Anti-CD2 MAb (Clone 5)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS13406)
- Anti-TNFRSF17 MAb (Clone 21)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS4020)
- Anti-KDR MAb (Clone 1)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS9678)
- Anti-CD33 MAb (Clone 22)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS5645)
- Anti-CD4 MAb (Clone 26)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS16539)
- Anti-MSTN MAb (Clone 11)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS12196)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.